Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Curevac N.V.
(NQ:
CVAC
)
3.100
+0.060 (+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Curevac N.V.
< Previous
1
2
3
Next >
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
November 12, 2024
Via
ACCESSWIRE
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
November 07, 2024
Via
ACCESSWIRE
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
November 04, 2024
Via
ACCESSWIRE
CureVac to Present at the 12th International mRNA Health Conference
November 04, 2024
Via
ACCESSWIRE
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 28, 2024
Via
ACCESSWIRE
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
September 13, 2024
Via
ACCESSWIRE
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
September 12, 2024
Via
ACCESSWIRE
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
August 15, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
August 15, 2024
Via
ACCESSWIRE
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
September 09, 2024
Via
ACCESSWIRE
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
August 15, 2024
Via
ACCESSWIRE
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
July 11, 2024
Via
ACCESSWIRE
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
July 03, 2024
Via
ACCESSWIRE
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
July 02, 2024
Via
ACCESSWIRE
CureVac Announces Voting Results of General Meeting
June 24, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
May 23, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
November 14, 2023
Via
ACCESSWIRE
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
May 28, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
April 24, 2024
Via
ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
April 24, 2024
Via
ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
April 24, 2024
Via
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
April 18, 2024
Via
ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
April 16, 2024
Via
ACCESSWIRE
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
April 04, 2024
Via
ACCESSWIRE
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
January 05, 2024
Via
ACCESSWIRE
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
December 19, 2023
Via
ACCESSWIRE
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
November 01, 2023
Via
ACCESSWIRE
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
August 17, 2023
Via
ACCESSWIRE
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
August 01, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.